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ABSTRACT
Purpose To compare the quality of therapeutic erythropoi-
etin (EPO) products, including two biosimilars, with respect
to content, aggregation, isoform profile and potency.
Methods Two original products, Eprex (epoetin alfa) and
Dynepo (epoetin delta), and two biosimilar products, Binocrit
(epoetin alfa) and Retacrit (epoetin zeta), were compared using
(1) high performance size exclusion chromatography, (2)
ELISA, (3) SDS-PAGE, (4) capillary zone electrophoresis and
(5) in-vivo potency.
Results Tested EPO products differed in content, isoform
composition, and potency.
Conclusion Of the tested products, the biosimilars have the
same or even better quality as the originals. Especially, the
potency of originals may significantly differ from the value on
the label.
KEY WORDS biosimilar.immunogenicity.protein
characterization.recombinanthumanerythropoietin
ABBREVIATIONS
CHO Chinese hamster ovary
CZE capillary zone electrophoresis
ELISA enzyme linked immunosorbent assay
EPAR European public assessment report
EPO Erythropoietin
HP-SEC high performance size exclusion chromatography
IU international units
PRCA pure red cell aplasia
SDS-
PAGE
sodium dodecyl sulfate polyacrylamide gel
electrophoresis
INTRODUCTION
Biologicals are increasingly used to treat diseases such as
multiple sclerosis, rheumatoid arthritis, cancer and
anemia. Since the patent protection of several biologicals
has expired, so-called biosimilars have been introduced
onto the market. Biosimilars are attempted copies of the
original product, but due to the complex structure and
intricate manufacturing processes of protein drugs, they
are only similar to the original product (1,2). The degree
of similarity between the original product and its bio-
similar is more difficult to assess than between an original
small molecule pharmaceutical and its generic version.
Therefore, clinical data acquired from the original
biological cannot necessarily be extended to its biosimilar
(s). The European Medicines Agency has acknowledged
this issue and published specific guidelines regarding
efficacy, safety and quality for the development of
biosimilar products (3).
Immunogenicity is an important issue when developing
and producing biologicals. This is also the case with
epoetins (EPOs), for which antibody formation can have
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EPO product Eprex was changed. The excipient human
serum albumin was replaced by polysorbate 80 and glycine,
which in more than 200 patients led to the formation of
neutralizing antibodies, which cross-neutralized their endog-
enous erythropoietin (4,5). As a result, pure red cell aplasia
(PRCA) developed. The cause of the increased immuno-
genicity of Eprex is still under debate (6–9), although the
increased tendency for aggregation in the new formula-
tion is considered the most likely explanation, together
with the subcutaneous route of administration (10). In
fact, antibody-mediated PRCA is an ongoing issue for all
EPO products. In Thailand, multiple EPO-associated
PRCA cases have been reported. Also here, aggregates
induced by improper storage could have contributed to
the development of PRCA. Praditpornsilpa and colleagues
showed a correlation between the development of PRCA
and the HLA-DRB1*09-DQB1*0309 gene, which is more
abundant in the Thai population compared to the
Caucasian population (11).
Since 2007, the patent protection of Eprex has expired,
and several biosimilar EPO products have entered the
market. As these products are similar, but not identical to
Eprex, one of the concerns is immunogenicity and PRCA.
The quality, including the level of aggregates of biosimilar
EPOs, is an important issue.
Our aim was to compare the quality of four different
EPO products: two original products, Eprex and Dynepo,
and two Eprex biosimilars, Binocrit and Retacrit. Because
a limited amount of EPO products was available, we were
restricted to the common assays used for quality control:
high performance size exclusion chromatography (HP-
SEC) to assess monomer and aggregate content, ELISA to
determine EPO protein content, SDS-PAGE under non-
reducing conditions to detect possible fragmentation and
covalent protein aggregates, capillary zone electrophoresis
(CZE) for isoform profiling and a normocythemic mouse
assay to test for potency.
MATERIALS AND METHODS
EPO Products
Four different EPO products, Eprex and Dynepo (original
products), as well as Binocrit and Retacrit (biosimilars) were
ordered via the Utrecht Medical Center pharmacy
(Utrecht, the Netherlands) and stored according to manu-
facturers’ specifications. Prefilled syringes containing
10,000 IU were used; syringes of Exprex, Binocrit and
Retacrit contained 1 ml of 10,000 IU/ml, syringes of
Dynepo contained 0.5 ml of 20,000 IU/ml. All tests were
performed before the expiry date. An overview of the
products, including lot no. and excipient composition, is
given in Table I.
High Performance Size-Exclusion Chromatography
(HP-SEC)
HP-SEC was used to assess the monomer content of the
four EPO products. Analysis was performed on an Agilent
1200 system (Agilent Technologies, Palo Alto, CA, USA)
combined with a Wyatt Eclipse (Wyatt Technology Europe
GmbH, Dernbach, Germany). A TSK Gel 3000 SWXL
column (300×7.8 mm) with a TSK Gel 3000 pre column
(Tosoh Biosep, Stuttgart, Germany) was used. Fifty μlo f
the formulations were injected, and separation was per-
formed at a flow rate of 0.5 ml/min. The running buffer
was composed of 50 mM sodium phosphate, 300 mM
sodium chloride, and 0.05% sodium azide (pH 7.0).
UV and fluorescence detectors were part of the Agilent
1200 system (Agilent Technologies, Palo Alto, CA, USA).
UV detection was performed at 280 nm. For fluorescence
detection, excitation was performed at 280 nm, and the
emission was recorded at 340 nm. Multi angle laser light
scattering (MALLS) detection was performed with an 18
angle detector (DAWN® HELEOS™, Wyatt Technology
Europe GmbH, Dernbach, Germany) operating with a
50 mW solid state laser at 658 nm. The protein content was
determined from the UV280 nm signal, using a molar
extinction coefficient of 22,600 M
−1cm
−1 (12). One IU EPO
equals 7.85 ng EPO protein.
Enzyme-Linked Immunosorbent Assay (ELISA)
A sandwich ELISA to detect human EPO (Quantikine IVD
Erythropoietin ELISA, R&D Systems, Abingdon, UK) was
used to assess the EPO protein content. In short, micro titer
plates pre-coated with anti-EPO antibody were incubated
with an EPO standard or a dilution series of each EPO
product. After washing, wells were incubated with an anti-
human EPO antibody (rat polyclonal) conjugated to
horseradish peroxidase. Wells were again washed, and a
substrate solution containing tetramethylbenzidine was
added. The reaction was stopped by the addition of sulfuric
acid solution. Optical density at 450 nm was measured
using a Biorad Novapath™ Microplate Reader (Bio-Rad
Laboratories, Veenendaal, The Netherlands). All data were
corrected for background, and a standard curve was
generated using the supplied EPO standards with known
IU per milliliter. EPO concentration of the four products
was assessed by comparing their optical density to the
standard curve. Average EPO content of three separate
dilution series was calculated. One-way ANOVA with
Tukey HSD post hoc was used to detect statistical differ-
ences between EPO products. In addition, EPO serum
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correctness of the procedure.
SDS-PAGE (Non-reducing)
To assess fragmentation and covalent aggregation of the
four EPO products, SDS-PAGE was performed under non-
reducing conditions. The procedure was adapted from
Bollag and colleagues (13). In short, all EPO products were
applied to a stacking gel (5% polyacrylamide) and running
gel (10% polyacrylamide). Loading solutions of Eprex,
Binocrit and Retacrit included 9 μl EPO product and 2 μl
sample buffer (containing Tris–HCl pH 6.8, glycerol, SDS
water and bromophenol blue), except Dynepo, of which
5 μl product was used (to prevent overloading due to two-
fold higher potency per ml). All samples were denatured
at 95°C for 10 min, and subsequently spinned down (1 min,
13,000 rpm) before loading them on gel. Separation took
place using 100 V. Proteins were visualized by silver staining.
PageRuler prestained protein ladder from Fermentas
(Burlington, USA) was used as reference for molecular
weight.
Capillary Zone Electrophoresis (CZE)
To assess isoform distribution of the EPO products, CZE
was performed according to the European Pharmacopoeia
(Ph. Eur.) monograph for erythropoietin concentrated
solutions. Slight modifications on the capillary temperature
and regeneration as proposed by Zhang and colleagues
were included in order to improve robustness and repro-
ducibility (14). All EPO samples were desalted and
concentrated by a nanosep centrifugal device (Pall Life
Sciences, Ann Arbor, USA) using the method described in
the Ph. Eur. monograph.
The CZE analysis was performed on a ProteomeLab™
PA800 with UV detector equipped with 32Karat (version
7.0) software from Beckman Coulter (Fullerton, CA, USA).
A bare fused-silica capillary (100 cm effective length×
50 μm id) from Polymicro Technologies (Phoenix, AZ,
USA) was used for separation. The background electrolyte
(BGE), separation voltage and UV detection were accord-
ing to the Ph. Eur. method (15). The BGE consisted of
0.01 M sodium chloride, 0.01 M tricine, 0.01 M sodium
acetate, 7 M urea and 2.5 mM putrescine, adjusted to
pH 5.5 with Acetic acid glacial 50% v/v at 30°C and
filtered through a 0.45-μm filter (Grace Davison Discovery
Science, IL, USA). The capillary temperature was set at
25°C, and a separation voltage of 15.7 kV was applied. The
four EPO products were injected hydrodynamically at
0.7 psi for 60 s, followed by a water injection at 0.1 psi for
3 s. UV detection was performed at 214 nm. The sampling
rate was 2 Hz. Isoform profiles of all products were assessed
during three independent runs. System suitability was
assessed by injection of a reference EPO (European
Directorate for the Quality of Medicines, Strasbourg,
France) in triplicate.
In Vivo Potency Testing
The potency assessment was based on measurement of the
stimulation of reticulocyte production in normocythaemic
mice (Pharmeuropa 8:371 (1996)). In short, EPO standard
with known potency (Second WHO International Standard
for rEPO, coded 88/574 from NIBSC, UK) and the four
EPO products were diluted into a high, middle and low
concentration and injected subcutaneously in female
BALB/c mice (n=6 per dilution, total of 90 mice, weighing
17–21 g). After 5 days, blood was isolated from the orbital
sinus, and reticulocyte concentration as percentage of total
erythrocyte concentration was determined. Potency of the
four products was calculated by comparing relative retic-
ulocyte concentration of the standard with the relative
reticulocyte concentration of the four EPO products. All
Lot no. Declared potency
(IU/ml)
Excipients
Eprex 7fst700 10,000 Sodium phosphate dibasic dihydrate, sodium phosphate
monobasic dihydrate, sodium chloride, glycine,
polysorbate 80
Binocrit 151107 10,000 Sodium phosphate dibasic dihydrate, sodium phosphate
monobasic dihydrate, sodium chloride, glycine,
polysorbate 80
Retacrit 7M008C8 10,000 Sodium phosphate dibasic dihydrate, sodium phosphate
monobasic dihydrate, sodium chloride, polysorbate 20,
glycine, leucine, isoleucine, threonine, phenylalanine,
glutamic acid
Dynepo 634022a 20,000 Sodium phosphate monobasic monohydrate, Sodium
phosphate dibasic heptahydrate, polysorbate 20,
sodium chloride
Table I Lot Number, Declared
Potency and Excipients of the Four
EPO Products Tested
388 Brinks et al.animal testing was in strict compliance with the principles
of laboratory animal care and was performed at the
NIBSC, UK. Transport of the EPO products to the
NIBSC was performed by a certificated courier.
RESULTS AND DISCUSSION
HP-SEC
HP-SEC is a routinely used analytical technique in quality
control to assess monomer and soluble aggregate content of
proteins in pharmaceutical preparations. In this study, HP-
SEC was applied to measure the monomer content of the
four EPO products (Table II). The EPO monomer eluted
at about 19.5 min (Fig. 1), and from MALLS detection a
molar mass of about 30 kDa was obtained for the monomer
peak for all products (data not shown). No aggregates or
fragments could be identified by HP-SEC in all four EPO
products. As expected, Dynepo showed a two-fold higher
EPO monomer content compared to Eprex, Binocrit and
Retacrit. EPO monomer content of Eprex was approxi-
mately 12% higher compared to Retacrit. Eprex and
Binocrit EPO monomer content was similar. The ratio
between the total AUC of the fluorescence detection and
total AUC UV detection at 280 nm was comparable for all
tested products, ranging from 6.57 to 6.74, pointing at
similar structural properties (Table II).
EPO monomer content determination by HP-SEC
could be affected by the matrix. As such, the different
formulations/matrixes of the EPO products could have
introduced formulation-specific changes in EPO monomer
content determination. However, content assessment by
ELISA, which is much less affected by these matrix effects,
corresponds to the results found for HP-SEC (data shown
later). Therefore, matrix effects on monomer content
determination by HP-SEC appear minimal.
Enzyme-Linked Immunosorbent Assay (ELISA)
In addition to the HP-SEC analysis to measure EPO
monomer content, an ELISA was performed to determine
the EPO protein content. Statistical analysis revealed
significant differences in EPO content between the products
(p<0.001). As expected, Dynepo had a significantly higher
EPO content compared to all other products (Table II, p=
0.001), which supported HP-SEC results. Eprex and
Binocrit showed a similar EPO content, while EPO content
in Retacrit tended to be lower than in Eprex (p=0.06). This
is supported by the HP-SEC data.
SDS-PAGE
Non-reducing SDS-PAGE was used to detect possible
fragmentation and covalent aggregation in the EPO
products. No fragments or aggregates were found on the
gel after silver staining (Fig. 2). Bands present around 34–
40 kDa corresponded to the theoretical molecular mass for
the EPO monomer (16). Similar molecular mass was also
observed during HP-SEC/MALLS analysis. The EPO
monomer consists of a polypeptide chain of approximately
18.4 kDa, with one O-linked and three N-linked glycosyl-
ation sites to which heterogeneous glycans are attached.
Unlike the other tested products, Binocrit showed at least
one additional band around 30 kDa (Fig. 2), suggesting
distinct isoform(s). The European Public Assessment Report
(EPAR) of Binocrit indeed states that Binocrit contains
more high-mannose structures than Eprex (17); however, it
is unlikely that these structures would contribute to an
additional band around 30 kDa but rather appear at a
higher molecular mass.
SDS-PAGE analysis did not show the presence of
covalent aggregates. As large covalent aggregates could
accumulate in the stacking gel, the stacking gel was also
stained for proteins. However, no aggregates were detected
(data not shown).
CZE
CZE separation relies on differences in protein charge-to-
size ratio. Under the applied CZE conditions, EPO will be
denatured, and the various isoforms will be separated based
on differences in number of charged groups, such as sialic
acid residues. The Ph. Eur. method to separate different
isoforms of EPO, with the modification of Zhang and
colleagues (14), was applied here. This method provides
Table II Comparison of Content and Potency of the Four EPO Products Tested
Declared potency
(IU/ml)
Content HP-SEC,
UV280nm (IU/ml)
Content ELISA (IU/ml) In Vivo potency (IU/ml) Ratio total AUC fluorescence/total
AUC UV280 nm from HP-SEC
Eprex 10,000 11,699±453 13,694±273 12,884 (10,860–15,285) 6.57±0.37
Binocrit 10,000 10,961±162 12,942±216 11,404 (9,458–13,752) 6.62±0.27
Retacrit 10,000 9,586±103 11,122±20 11,016 (8,942–13,571) 6.74±0.07
Dynepo 20,000 20,564±269 23,208±906 15,694 (13,421–18,352) 6.60±0.11
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Fig. 1 HP-SEC chromatograms of the EPO products using UV detection at 280 nm (A), fluorescence detection (Exc. 280 nm, Em. 340 nm) (B) and
MALLS detection (C). Inserts show a zoom into the chromatograms.
390 Brinks et al.reproducible migration times, making it possible to reliably
annotate and compare isoform peaks among the four EPO
products. Isoforms migrated between 61 and 74 min, with
clear product differences (Fig. 3). In Eprex, Binocrit and
Retacrit 6 isoforms were observed, while Dynepo consists of
9 isoforms. In addition to the different number of isoforms,
the products showed different isoform ratios. In Eprex,
isoform 5 and 6 were most abundant; in Retacrit, isoform 5;
in Binocrit (Eprex biosimilar), isoform 6; and in Dynepo,
isoforms 6 and 7 were most abundant (Fig. 3). The
difference in isoform ratio between Eprex and Binocrit
could be due to the presence of more high-mannose
structures in Binocrit compared to Eprex (17). However,
the exact isoform content of the different peaks could not
be determined here. Another explanation could be batch-
to-batch differences in glycosylation we have shown before
for other EPO products (2).
Up to now we have not been able to assign specific
isoforms including glycan identification to the peaks,
making it impossible to draw conclusions on the exact
nature of the differences in glycosylation pattern between
EPO products.
Glycosylation is strongly affected by the cell line in
which the proteins are produced. In the case of Eprex,
Binocrit and Retacrit, a Chinese hamster ovary (CHO)
cell line was used, while Dynepo was produced by a
human fibrosarcoma cell line. This likely explains why the
isoform composition of Dynepo was different from the
Fig. 3 CE-UV analysis of the four EPO products.
Fig. 2 SDS-PAGE gel of the four EPO products under non-reducing
conditions.
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possess N-glycolylneuraminic acid (Neu5Gc), which is
present in CHO derived products (18).
Potency
Using a validated normocythemic mouse assay, the potency
of the four EPO products was assessed in vivo. Binocrit and
Retacrit had a slightly higher potency than declared on the
package (Table II). The potency of Eprex was higher than
declared (129%), whereas the potency of Dynepo was lower
than declared (78%).
Both HP-SEC and ELISA data showed approximately
two-fold higher protein concentrations in Dynepo com-
pared to the other products, suggesting that the low
potency of Dynepo was due to a lower specific activity.
Possible Biological Implications of the Differences
Between Products
Within this study, we showed that Eprex, Binocrit, Retacrit
and Dynepo differ in content, isoform profiles and potency.
What these differences mean for clinical efficacy and safety
of EPO products is speculative (4,5).
The differences in isoform profiles between the tested
EPO products represent distinct glycosylation, which likely
originated from different cell lines used to produce the
protein. Glycosylation is a post-translational modification of
proteins that has the ability to affect stability, pharmacoki-
netics, and immunogenic properties of the protein (19,20).
Glycosylation could therefore affect the occurrence of
antibody responses in patients. In the case of EPO,
glycosylation has also been found to affect potency (21,
22). Particularly the N-linked sugar chains seem important
for biological activity of EPO. As such, distinct glycosylation
variations between the EPO products shown by different
isoforms can also contribute to the differences in potency.
An unexpected finding was the low potency of Dynepo
and the higher potency of Eprex than declared on the
package (respectively, 78% and 129%). The reason for this
is speculative, but such deviations in potency can lead to
significant under- or overdosing for the patients. High EPO
doses have been correlated with increased mortality in
anemia patients (23); however, this is also under debate
(24). In extreme cases, overdosing can lead to dangerously
high hematocrit values (25).
Besides possible implications of glycosylation on immu-
nogenicity, previous studies have shown that leachates and
aggregates in particular are implied in anti-EPO antibody
response (6,7,26). However, we do not detect any aggre-
gates in the four tested EPO products using HP-SEC and
SDS-PAGE, suggesting that the risk of aggregate-induced
immune response in these tested products is low.
We showed that the EPO products differ in glycosyla-
tion, potency and content using a single batch of the
products. Before, we have shown that batch-to-batch
differences in glycosylation can be profound (2). Therefore,
future studies assessing batch-to-batch differences seem
necessary. Additionally, current study assessed the quality
of four EPO products available on the European market,
while more EPO products are present on European, US
and other markets (for example Epogen, epoetin alfa
produced by Genzyme, or Neorecormon, epoetin beta
produced by Roche). Testing these products would
give additional insight in the quality of available EPO
products.
CONCLUSION
This study shows that the quality of biosimilars is high. The
tested EPO products have major differences in potency and
display distinct isoform profiles. However, the possible impact
of different isoform composition on immunogenicity needs
further investigation. An unexpected finding was that potency
of Eprex and Dynepo (original products) is respectively higher
and lower than stated on the label. Therefore, substitution of
EPO products should be performed with care and with
monitoring of patients. In addition, regular physicochemical
and biological analysis of the products, even when they are on
the market, is necessary to monitor product quality and
evaluate potential immunogenic factors.
Conflict of Interest This research was sponsored by Roche.
H.S. has given presentations during congresses sponsored by
companies producing epoetin products. The research group
at the Department of Pharmaceutics, Utrecht Institute for
Pharmaceutical Sciences (UIPS), Utrecht University has
received grants funded by Roche, Hospira, Organon and
Merck-Serono. V.B., A.H., A.H.H.B., L.J.R., R.H., G.W.S.
and W.J. declare no conflict of interest.
Open Access This article is distributed under the terms of
the Creative Commons Attribution Noncommercial License
which permits any noncommercial use, distribution, and
reproduction in any medium, provided the original author(s)
and source are credited.
REFERENCES
1. Schellekens H. How similar do ‘biosimilars’ need to be? Nat
Biotechnol. 2004;22:1357–9.
2. Schellekens H. Biosimilar epoetins: how similar are they? Eur J
Hosp Pharm. 2004;3:43–7.
392 Brinks et al.3. EMEA/CHMP/94528/2005. Guideline on similar biological
medicinal products. In 2005.
4. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson
AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia:
past, present, and future considerations. Transfusion.
2008;48:1754–62.
5. Schellekens H. Immunologic mechanisms of EPO-associated pure
red cell aplasia. Best Pract Res Clin Haematol. 2005;18:473–80.
6. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall
N. Epoetin-associated pure red cell aplasia in patients with
chronic kidney disease: solving the mystery. Nephrol Dial
Transplant. 2005;20 Suppl 3:iii33–40.
7. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-
associated protein in epoetin formulations: a risk factor for
immunogenicity? Pharm Res. 2003;20:1903–7.
8. Hermeling S, Jiskoot W, Crommelin DJ, Schellekens H. Reaction
to the paper: interaction of polysorbate 80 with erythropoietin: a
case study in protein-surfactant interactions. Pharm Res.
2006;23:641–2.
9. Schellekens H. Erythropoietic proteins and antibody-mediated
pure red cell aplasia: a potential role for micelles. Nephrol Dial
Transplant. 2004;19:2422.
10. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still
an unsolved mystery. J Immunotoxicol. 2006;3:123–30.
11. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh
O, Jootar S, Intarakumthornchai T, et al. The association of anti-r-
HuEpo-associated pure red cell aplasia with HLA-DRB1*09-
DQB1*0309. Nephrol Dial Transplant. 2009;24:1545–9.
12. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization
of the extracellular domain of the erythropoietin (EPO) receptor
by EPO: one high-affinity and one low-affinity interaction.
Biochemistry. 1996;35:1681–91.
13. Bollag DM, Edelstein SJ. Protein methods. New York: Wiley-Liss;
1991.
14. Zhang J, Chakraborty U, Villalobos AP, Brown JM, Foley JP.
Optimization and qualification of capillary zone electrophoresis
method for glycoprotein isoform distribution of erythropoietin
for quality control laboratory. J Pharm Biomed Anal.
2009;50:538–43.
15. European Pharmacopoeia 2. In 2005, pp. 1528–9.
16. Lacombe C, Mayeux P. Biology of erythropoietin. Haematolog-
ica. 1998;83:724–32.
17. European Medicines Evaluation Agency.HX575.Scientific discus-
sion. Available at www emea europa eu/humandocs/PDFs/EPAR/
epoetinalfahexal/H-726-. (2007).
18. Llop E, Gutierrez-Gallego R, Segura J, Mallorqui J, Pascual JA.
Structural analysis of the glycosylation of gene-activated erythro-
poietin (epoetin delta, Dynepo). Anal Biochem. 2008;383:243–54.
19. Brooks SA. Strategies for analysis of the glycosylation of proteins:
current status and future perspectives. Mol Biotechnol.
2009;43:76–88.
2 0 . T o y o d aT ,I t a iT ,A r a k a w aT ,A o k iK H ,Y a m a g u c h iH .
Stabilization of human recombinant erythropoietin through
interactions with the highly branched N-glycans. J Biochem.
2000;128:731–7.
21. Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T,
et al. Role of glycosylation on the secretion and biological activity
of erythropoietin. Biochemistry. 1992;31:9871–6.
22. Takeuchi M, Inoue N, Strickland TW, Kubota M, Wada M,
Shimizu R, et al. Relationship between sugar chain structure and
biological activity of recombinant human erythropoietin produced
in Chinese hamster ovary cells. Proc Natl Acad Sci USA.
1989;86:7819–22.
23. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D,
Kaufman J. Hematocrit was not validated as a surrogate end
point for survival among epoetin-treated hemodialysis patients. J
Clin Epidemiol. 2004;57:1086–95.
24. BradburyBD,DoTP,WinkelmayerWC,CritchlowCW,Brookhart
MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk
among hemodialysis patients with hemoglobin levels less than 11 g/
dL. Pharmacoepidemiol Drug Saf. 2009;18:932–40.
25. Brown KR, Carter Jr W, Lombardi GE. Recombinant erythro-
poietin overdose. Am J Emerg Med. 1993;11:619–21.
26. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin
DJ, Jiskoot W. Antibody response to aggregated human interferon
alpha2b in wild-type and transgenic immune tolerant mice
depends on type and level of aggregation. J Pharm Sci.
2006;95:1084–96.
Quality of Original and Biosimilar Epoetin Products 393